XNCR Stock: Price, Earnings History and SEC Filings
Xencor, Inc. (XNCR) last traded at $29.82, up 2.09% on the latest session and up 19.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.29 against an analyst estimate of $-0.82, a beat of 64.6%.
$29.82 +2.09%
1 month+19.52%
52-week high$33.60
52-week low$10.38
Volume1.29M
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
XNCR earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $-0.29 | $-0.82 | +64.63% |
| Mar 2026 | May 6, 2026 | $-1.71 | $-0.65 | -163.08% |
| Dec 2025 | Feb 25, 2026 | $-0.09 | $-0.64 | +85.94% |
| Sep 2025 | Nov 5, 2025 | $-0.08 | $-0.72 | +88.89% |
XNCR beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for XNCR
SEC filing data is not available right now. You can search for XNCR on SEC EDGAR.
XNCR news
- Xencor Sees Upside Potential After 'Exciting' Kidney Cancer Trial Data, RBC Capital Markets SaysOct 27, 2026 · finance.yahoo.com
- Xencor advances XmAb819 solid-tumor T-cell engagerOct 27, 2026 · theglobeandmail.com
- Xencor (XNCR) Is Up 15.8% What's Changed After Kidney Cancer Trial UpdateOct 26, 2026 · finance.yahoo.com
- Xencor Catapults On 'Unprecedented,' 'Profound' Cancer DataOct 26, 2026 · finance.yahoo.com
- Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney CancerOct 26, 2026 · marketbeat.com
- Xencor Soars 31% on Kidney Cancer Trial Data Showing “Impressive Antitumor Activity”Oct 26, 2026 · tikr.com
- Sector Update: Healthcare Stocks Softer Monday AfternoonOct 26, 2026 · finance.yahoo.com
- Top Midday GainersOct 26, 2026 · finance.yahoo.com
About Xencor, Inc.
Xencor, Inc. (XNCR) is a US-listed public company on Nasdaq.